Abingdon Health plc logo

Abingdon Health plc (ABDX)

Market Closed
19 Jun, 15:30
LSE LSE
11. 25
GBX
-0.25
-2.1739%
GBX
17.53M Market Cap
- P/E Ratio
- Div Yield
255,386 Volume
- Eps
11.5 GBX
Previous Close
Add Transaction
Day Range
11 12
Year Range
5.1 13
Want to track ABDX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

ABDX closed today lower at 11.25 GBX, a decrease of -2.1739% from yesterday's close, completing a monthly decrease of -6.25% or -0.75 GBX. Over the past 12 months, ABDX stock gained 75.7812%.
ABDX is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on LSE (GBX).

ABDX Chart

People also search for

IKA
Ilika Plc
31 GBX
-3.125%
Hercules Site Services Plc
24.5 GBX
-5.7692%
SYS
SysGroup PLC
18 GBX
0%
VEL
Velocity Composites Plc
15 GBX
+3.4483%
Verici Dx plc
0.38 GBX
0%

Abingdon Health plc (ABDX) FAQ

What is the stock price today?

The current price is 11.25 GBX.

On which exchange is it traded?

Abingdon Health plc is listed on LSE.

What is its stock symbol?

The ticker symbol is ABDX.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 17.53M.

Has Abingdon Health plc ever had a stock split?

No, there has never been a stock split.

Abingdon Health plc Profile

Professional Services Industry
Industrials Sector
Mr. Chris Henry Francis Yates CEO
LSE Exchange
- ISIN
United Kingdom Country
84 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Abingdon Health Plc is a leading entity that specializes in the development, manufacture, and distribution of diagnostic devices, serving an international clientele including regions such as the United Kingdom, the United States, Canada, Europe, and beyond. Established in 2008 and headquartered in York, the United Kingdom, the company is at the forefront of providing innovative solutions in diagnostics, covering a wide array of needs from fertility, health and well-being, to infectious diseases, drug testing, and plant health. Furthermore, Abingdon Health Plc prides itself on its strategic collaborations with significant partners like DeepVerge plc and Vatic Health Limited, enhancing its capabilities in the development, manufacturing, and commercialization of lateral flow tests, thus cementing its role in the diagnostics sector.

Products and Services

  • Abingdon Simply Test

    A diverse range of self-tests designed for consumers covering fertility, health and well-being, infectious diseases, and drug testing. These tests are crafted to provide quick and reliable results, facilitating early detection and wellness monitoring.

  • PCRD and PCRD FLEX

    Nucleic acid lateral flow tests that offer rapid results post isothermal amplification. These tests are pivotal for various applications, enabling quick decision-making processes in clinical, research, and industrial settings.

  • 2019-nCoV Antigen Test

    A rapid lateral flow test for the qualitative detection of antigens to SARS-CoV-2. Designed for efficiency and accuracy, this test plays a crucial role in managing and controlling the spread of COVID-19 by facilitating quick diagnoses.

  • Plant Health Tests

    Diagnostic tests tailored to meet the needs of the agriculture sector, focusing on the health and productivity of plants. These tests are essential for early detection of diseases, ensuring the well-being of crops and securing food supply chains.

  • Nucleic Acid Lateral Flow Immunoassays

    These assays are a part of the company’s broader range of diagnostic tests, which include customized solutions for detecting nucleic acids rapidly and efficiently.

  • AppDx

    A customizable image capturing technology that transforms smartphones into self-sufficient, standalone lateral-flow readers. This innovation democratizes the application of lateral flow assays, offering a practical solution for point-of-care testing.

  • Salistick

    A revolutionary rapid saliva-based pregnancy test. This product exemplifies the company's dedication to innovating within the diagnostics space, offering a more convenient and non-invasive testing option for pregnancy detection.

  • Contract Manufacturing and Services

    Abingdon Health Plc extends its expertise through a wide array of services including contract manufacturing, nucleic acid lateral flow test customization, and lateral flow development and manufacturing services. This comprehensive service offering supports businesses at various stages of product development and market launch.

  • Regulatory Consultancy Services

    The company also offers regulatory consultancy services, providing essential support and guidance for businesses navigating the complex regulatory environment of the diagnostics sector. This service ensures that products meet all necessary standards and regulations for market entry.

Contact Information

Address: York Biotech Campus
Phone: 44 19 0440 6050